Progressively impaired proteasomal capacity during terminal plasma cell differentiation

[1]  H. Ploegh,et al.  XBP-1 specifically promotes IgM synthesis and secretion, but is dispensable for degradation of glycoproteins in primary B cells , 2005, The Journal of experimental medicine.

[2]  P. Kloetzel,et al.  Differential Expression Regulation of the α and β Subunits of the PA28 Proteasome Activator in Mature Dendritic Cells1 , 2005, The Journal of Immunology.

[3]  Maurizio Molinari,et al.  EDEM Contributes to Maintenance of Protein Folding Efficiency and Secretory Capacity* , 2004, Journal of Biological Chemistry.

[4]  K. Mori,et al.  XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. , 2004, The Journal of cell biology.

[5]  L. Staudt,et al.  XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. , 2004, Immunity.

[6]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[7]  T. Giese,et al.  Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. , 2004, Blood.

[8]  Michael Butterworth,et al.  Caspase activation inhibits proteasome function during apoptosis. , 2004, Molecular cell.

[9]  Andreas Radbruch,et al.  Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice , 2004 .

[10]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[11]  I. Braakman,et al.  Quality control in the endoplasmic reticulum protein factory , 2003, Nature.

[12]  A. Strasser,et al.  Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. , 2003, Annual review of immunology.

[13]  C. Tunyaplin,et al.  Regulatory mechanisms that determine the development and function of plasma cells. , 2003, Annual review of immunology.

[14]  G. Shore,et al.  Regulation of apoptosis by endoplasmic reticulum pathways , 2003, Oncogene.

[15]  Neal N. Iwakoshi,et al.  Proteasome inhibitors disrupt the unfolded protein response in myeloma cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Glimcher,et al.  The X‐box binding protein‐1 transcription factor is required for plasma cell differentiation and the unfolded protein response , 2003, Immunological reviews.

[17]  K. Lindsten,et al.  A transgenic mouse model of the ubiquitin/proteasome system , 2003, Nature Biotechnology.

[18]  O. Sezer,et al.  Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion , 2003, Journal of Cancer Research and Clinical Oncology.

[19]  P. Kloetzel,et al.  Inhibition of Proteasome Activity Induces Concerted Expression of Proteasome Genes and de Novo Formation of Mammalian Proteasomes* , 2003, Journal of Biological Chemistry.

[20]  S. Kasibhatla,et al.  Why target apoptosis in cancer treatment? , 2003, Molecular cancer therapeutics.

[21]  P. Richardson,et al.  Targeting proteasome inhibition in hematologic malignancies. , 2003, Reviews in clinical and experimental hematology.

[22]  Y. Hannun,et al.  BcR-induced Apoptosis Involves Differential Regulation of C16 and C24-Ceramide Formation and Sphingolipid-dependent Activation of the Proteasome* , 2003, The Journal of Biological Chemistry.

[23]  L. Hendershot,et al.  The stressful road to antibody secretion , 2003, Nature Immunology.

[24]  K. Rajewsky,et al.  Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1 , 2003, Nature Immunology.

[25]  Albert J R Heck,et al.  Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. , 2003, Immunity.

[26]  Hiderou Yoshida,et al.  A time-dependent phase shift in the mammalian unfolded protein response. , 2003, Developmental cell.

[27]  C. Morimoto,et al.  CD27 and CD40 Inhibit p53-independent Mitochondrial Pathways in Apoptosis of B Cells Induced by B Cell Receptor Ligation* , 2002, The Journal of Biological Chemistry.

[28]  T. Hideshima,et al.  Molecular mechanisms of novel therapeutic approaches for multiple myeloma , 2002, Nature Reviews Cancer.

[29]  Andreas Radbruch,et al.  Humoral immunity and long-lived plasma cells. , 2002, Current opinion in immunology.

[30]  P. Pierre,et al.  Transient aggregation of ubiquitinated proteins during dendritic cell maturation , 2002, Nature.

[31]  A. Goldberg,et al.  Not just research tools—proteasome inhibitors offer therapeutic promise , 2002, Nature Medicine.

[32]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[33]  A. Symeonidis,et al.  Determination of Plasma Cell Secreting Potential as an Index of Maturity of Myelomatous Cells and a Strong Prognostic Factor , 2002, Leukemia & lymphoma.

[34]  K. Fröhlich,et al.  AAA-ATPase p97/Cdc48p, a Cytosolic Chaperone Required for Endoplasmic Reticulum-Associated Protein Degradation , 2002, Molecular and Cellular Biology.

[35]  R. Sitia,et al.  Reduction of Interchain Disulfide Bonds Precedes the Dislocation of Ig-μ Chains from the Endoplasmic Reticulum to the Cytosol for Proteasomal Degradation* , 2001, The Journal of Biological Chemistry.

[36]  A. Macagno,et al.  Pronounced up‐regulation of the PA28α/β proteasome regulator but little increase in the steady‐state content of immunoproteasome during dendritic cell maturation , 2001, European journal of immunology.

[37]  Neal N. Iwakoshi,et al.  Plasma cell differentiation requires the transcription factor XBP-1 , 2001, Nature.

[38]  A. Goldberg,et al.  26S proteasomes and immunoproteasomes produce mainly N‐extended versions of an antigenic peptide , 2001, The EMBO journal.

[39]  R. Sitia,et al.  Glycoprotein Quality Control in the Endoplasmic Reticulum , 2001, The Journal of Biological Chemistry.

[40]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[41]  F. Belardelli,et al.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. , 2001, Immunity.

[42]  David Steven Scott,et al.  Activation-induced cell death in B lymphocytes , 2000, Cell Research.

[43]  R. Kopito,et al.  Aggresomes and Russell bodies , 2000, EMBO reports.

[44]  K. Lindsten,et al.  Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells , 2000, Nature Biotechnology.

[45]  Q. Dou,et al.  Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  C. Maggioni,et al.  Degradation of unassembled soluble Ig subunits by cytosolic proteasomes: evidence that retrotranslocation and degradation are coupled events , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  C. Crews,et al.  Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Melamed,et al.  Analysis of apoptosis by laser scanning cytometry. , 1999, Cytometry.

[49]  G. Klaus,et al.  Evidence for a critical role for IL-2 in CD40-mediated activation of naive B cells by primary CD4 T cells. , 1998, Journal of immunology.

[50]  W. Greene,et al.  Cotranslational Biogenesis of NF-κB p50 by the 26S Proteasome , 1998, Cell.

[51]  R. Sitia,et al.  Quality control of ER synthesized proteins: an exposed thiol group as a three‐way switch mediating assembly, retention and degradation. , 1993, The EMBO journal.

[52]  C. Alberini,et al.  Developmental regulation of IgM secretion: The role of the carboxy-terminal cysteine , 1990, Cell.

[53]  C. Milstein,et al.  Regulation of membrane IgM expression in secretory B cells: translational and post‐translational events. , 1987, The EMBO journal.

[54]  J. W. Brewer,et al.  Building an antibody factory: a job for the unfolded protein response , 2004, Nature Immunology.

[55]  C. Borner.  The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. , 2003, Molecular immunology.

[56]  A. Goldberg,et al.  Degradation of cell proteins and the generation of MHC class I-presented peptides. , 1999, Annual review of immunology.

[57]  W. Greene,et al.  Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome. , 1998, Cell.

[58]  T. Simmen,et al.  IgM polymerization inhibits the Golgi-mediated processing of the mu-chain carboxy-terminal glycans. , 1996, Molecular immunology.

[59]  J. Banchereau,et al.  The CD40 antigen and its ligand. , 1994, Annual review of immunology.

[60]  I. Maclennan,et al.  Distinct short‐lived and long‐lived antibody‐producing cell populations , 1986, European journal of immunology.